Liu Bing-Rong, Song Ji-Tao, Kong Ling-Jian, Pei Feng-Hua, Wang Xin-Hong, Du Ya-Ju
Department of Gastroenterology and Hepatology, The Second Affiliated Hospital of Harbin Medical University, 246 Xuefu Road, Nangang District, Harbin, 150086, People's Republic of China,
Surg Endosc. 2013 Nov;27(11):4354-9. doi: 10.1007/s00464-013-3023-3. Epub 2013 Jun 14.
Endoscopic resection of esophageal or cardial subepithelial tumors (SETs) originating from the muscularis propria (MP) is rarely done due to the high risk of perforation, fistula formation, and secondary infection. The aim of this study was to evaluate the preliminary clinical feasibility and safety of tunneling endoscopic muscularis dissection (tEMD) for resection of SETs located in the esophagus and gastric cardia
Twelve patients with SETs originating from the MP of the esophagus (n = 7) or cardia (n = 5) were treated by tEMD. The procedure included creation of a submucosal tunnel to reach the tumor, dissection of the tumor from the surrounding submucosal tissue and the unaffected MP layer, full-thickness resection of the tumor and affected MP, and subsequent closure of the tunnel mucosal entry with endoscopic clips.
The en bloc resection rate was 100 % (seven lesions affected the deep MP so complete MP resection was performed; five lesions affected the superficial MP for a partial MP resection). The average tumor size was 18.5 ± 6.9 (range 10-30) mm. The mean operating time was 78.3 ± 25.5 (range 50-130) min. The histological diagnoses were two gastrointestinal stromal tumors with very low risk, nine leiomyomas, and one schwannoma. Air leakage and effusion included subcutaneous and mediastinal emphysema in eight patients (66.7 %), pneumothorax in four (33.3 %), pneumoperitoneum in three (25.0 %), and small pleural effusion in two (16.7 %). All air leakage and effusion cases were resolved with conservative management. No patient developed delayed hemorrhage and chronic fistula after tEMD. During the mean follow-up time of 7.1 ± 4.3 (range 2-15) months, no tumor recurrence was found in any patient.
tEMD appears to be a feasible minimally invasive and effective treatment for patients with SETs originating from the MP layer of the esophagus and cardia.
由于穿孔、瘘管形成及继发感染风险高,源于固有肌层(MP)的食管或贲门黏膜下肿瘤(SETs)的内镜切除很少进行。本研究旨在评估隧道式内镜肌层剥离术(tEMD)切除位于食管和胃贲门的SETs的初步临床可行性和安全性。
12例源于食管MP(n = 7)或贲门MP(n = 5)的SETs患者接受了tEMD治疗。该手术包括创建一个黏膜下隧道以到达肿瘤,从周围黏膜下组织和未受影响的MP层剥离肿瘤,肿瘤及受影响MP的全层切除,以及随后用内镜夹封闭隧道黏膜入口。
整块切除率为100%(7个病变累及深层MP,因此进行了完整MP切除;5个病变累及浅层MP,进行了部分MP切除)。平均肿瘤大小为18.5±6.9(范围10 - 30)mm。平均手术时间为78.3±25.5(范围50 - 130)分钟。组织学诊断为2例极低风险胃肠道间质瘤、9例平滑肌瘤和1例神经鞘瘤。漏气和积液包括8例(66.7%)皮下和纵隔气肿、4例(33.3%)气胸、3例(25.0%)气腹和2例(16.7%)少量胸腔积液。所有漏气和积液病例均经保守治疗后缓解。tEMD后无患者发生迟发性出血和慢性瘘管。在平均7.1±4.3(范围2 - 15)个月的随访期内,未发现任何患者肿瘤复发。
tEMD似乎是一种可行的微创且有效的治疗方法,适用于源于食管和贲门MP层的SETs患者。